Time to Positivity Facilitates an Early Differential Diagnosis of Candida tropicalis from Other Candida species

References

• Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. Nat Rev Dis Primers. 2018;4:18026. doi:10.1038/nrdp.2018.26
   PubMed Web of Science ®Google Scholar
• Medina N, Soto-Debran JC, Seidel D, et al. MixInYeast: a multicenter study on mixed yeast infections. J Fungi. 2020;7(1):13. doi:10.3390/jof7010013
   Web of Science ®Google Scholar
• Pfaller MA, Andes DR, Diekema DJ, et al. Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004–2008. PLoS One. 2014;9(7):e101510. doi:10.1371/journal.pone.0101510
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol. 2010;48(4):1366–1377. doi:10.1128/JCM.02117-09
   PubMed Web of Science ®Google Scholar
• Kullberg BJ, Arendrup MC. Invasive Candidiasis. N Engl J Med. 2015;373(15):1445–1456. doi:10.1056/NEJMra1315399
   PubMed Web of Science ®Google Scholar
• Arendrup MC, Patterson TF. Multidrug-resistant candida: epidemiology, molecular mechanisms, and treatment. J Infect Dis. 2017;216(suppl_3):S445–S451. doi:10.1093/infdis/jix131
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol. 2013;51(8):2571–2581. doi:10.1128/JCM.00308-13
   PubMed Web of Science ®Google Scholar
• Arastehfar A, Hilmioglu-Polat S, Daneshnia F, et al. Recent Increase in the prevalence of fluconazole-non-susceptible candida tropicalis blood isolates in Turkey: clinical implication of azole-non-susceptible and fluconazole tolerant phenotypes and genotyping. Front Microbiol. 2020;11:587278. doi:10.3389/fmicb.2020.587278
   PubMed Web of Science ®Google Scholar
• Wang Y, Fan X, Wang H, et al. Continual decline in azole susceptibility rates in candida tropicalis over a 9-year period in China. Front Microbiol. 2021;12:702839. doi:10.3389/fmicb.2021.702839
   PubMed Web of Science ®Google Scholar
• Fan X, Xiao M, Liao K, et al. Notable increasing trend in azole non-susceptible Candida tropicalis causing invasive candidiasis in China (August 2009 to July 2014): molecular epidemiology and clinical azole consumption. Front Microbiol. 2017;8:464. doi:10.3389/fmicb.2017.00464
   PubMed Web of Science ®Google Scholar
• Munoz P, Giannella M, Fanciulli C, et al. Candida tropicalis fungaemia: incidence, risk factors and mortality in a general hospital. Clin Microbiol Infect. 2011;17(10):1538–1545. doi:10.1111/j.1469-0691.2010.03338.x
   Web of Science ®Google Scholar
• Tadec L, Talarmin JP, Gastinne T, et al. Epidemiology, risk factor, species distribution, antifungal resistance and outcome of candidemia at a single French hospital: a 7-year study. Mycoses. 2016;59(5):296–303. doi:10.1111/myc.12470
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1–e50. doi:10.1093/cid/civ933
   PubMed Web of Science ®Google Scholar
• Hof H. Developments in the epidemiolgy of invasive fungal infections - implications for the empiric and targeted antifungal therapy. Mycoses. 2008;51(Suppl 1):1–6. doi:10.1111/j.1439-0507.2008.01522.x
   Web of Science ®Google Scholar
• Martinez JA, Pozo L, Almela M, et al. Microbial and clinical determinants of time-to-positivity in patients with bacteraemia. Clin Microbiol Infect. 2007;13(7):709–716. doi:10.1111/j.1469-0691.2007.01736.x
   PubMed Web of Science ®Google Scholar
• Lai CC, Wang CY, Liu WL, et al. Time to blood culture positivity as a predictor of drug resistance in Acinetobacter baumannii complex bacteremia. J Infect. 2011;63(1):96–98. doi:10.1016/j.jinf.2011.05.009
   Web of Science ®Google Scholar
• Kassis C, Rangaraj G, Jiang Y, Hachem RY, Raad I. Differentiating culture samples representing coagulase-negative staphylococcal bacteremia from those representing contamination by use of time-to-positivity and quantitative blood culture methods. J Clin Microbiol. 2009;47(10):3255–3260. doi:10.1128/JCM.01045-09
   PubMed Web of Science ®Google Scholar
• Orihuela-Martin J, Rodriguez-Nunez O, Morata L, et al. Performance of differential time to positivity as a routine diagnostic test for catheter-related bloodstream infections: a single-centre experience. Clin Microbiol Infect. 2020;26(3):383e381–383 e387. doi:10.1016/j.cmi.2019.07.001
   Web of Science ®Google Scholar
• Kim SH, Yoon YK, Kim MJ, Sohn JW. Clinical impact of time to positivity for Candida species on mortality in patients with candidaemia. J Antimicrob Chemother. 2013;68(12):2890–2897. doi:10.1093/jac/dkt256
   PubMed Web of Science ®Google Scholar
• Cobos-Trigueros N, Morata L, Torres J, et al. Usefulness of time-to-positivity in aerobic and anaerobic vials to predict the presence of Candida glabrata in patients with candidaemia. J Antimicrob Chemother. 2013;68(12):2839–2841. doi:10.1093/jac/dkt285
   Web of Science ®Google Scholar
• Foster N, Symes C, Barton R, Hobson R. Rapid identification of Candida glabrata in Candida bloodstream infections. J Med Microbiol. 2007;56(Pt 12):1639–1643. doi:10.1099/jmm.0.47406-0
   Web of Science ®Google Scholar
• Yarbrough ML, Wallace MA, Burnham CD, Diekema DJ. Comparison of microorganism detection and time to positivity in pediatric and standard media from three major commercial continuously monitored blood culture systems. J Clin Microbiol. 2021;59(7):e0042921. doi:10.1128/JCM.00429-21
   Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. M60Ed1E Performance Standards for Antifungal Susceptibility Testing of Yeasts. Wayne, PA.: CLSI; 2017.
   Google Scholar
• Clinical and Laboratory Standards Institute. M59 Epidemiological Cutoff Values for Antifungal Susceptibility Testing. 1st ed. Wayne, PA: CLSI; 2016.
   Google Scholar
• Arastehfar A, Daneshnia F, Hafez A, et al. Antifungal susceptibility, genotyping, resistance mechanism, and clinical profile of Candida tropicalis blood isolates. Med Mycol. 2020;58(6):766–773. doi:10.1093/mmy/myz124
   Web of Science ®Google Scholar
• Arastehfar A, Shaban T, Zarrinfar H, et al. Candidemia among Iranian patients with severe COVID-19 admitted to ICUs. J Fungi. 2021;7(4):280. doi:10.3390/jof7040280
   Web of Science ®Google Scholar
• Zarrinfar H, Kaboli S, Dolatabadi S, Mohammadi R. Rapid detection of Candida species in bronchoalveolar lavage fluid from patients with pulmonary symptoms. Braz J Microbiol. 2016;47(1):172–176. doi:10.1016/j.bjm.2015.02.001
   Web of Science ®Google Scholar
• Arastehfar A, Daneshnia F, Kord M, et al. Corrigendum: comparison of 21-Plex PCR and API 20C AUX, MALDI-TOF MS, and rDNA sequencing for a wide range of clinically isolated yeast species: improved identification by combining 21-Plex PCR and API 20C AUX as an alternative strategy for developing countries. Front Cell Infect Microbiol. 2019;9:176. doi:10.3389/fcimb.2019.00176
   Web of Science ®Google Scholar
• Mikulska M, Calandra T, Sanguinetti M, et al. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit Care. 2010;14(6):R222. doi:10.1186/cc9365
   PubMed Web of Science ®Google Scholar
• Ellepola AN, Morrison CJ. Laboratory diagnosis of invasive candidiasis. J Microbiol. 2005;43:65–84.
   PubMed Web of Science ®Google Scholar
• Lei J, Xu J, Wang T. In vitro susceptibility of Candida spp. to fluconazole, itraconazole and voriconazole and the correlation between triazoles susceptibility: results from a five-year study. J Mycol Med. 2018;28(2):310–313. doi:10.1016/j.mycmed.2018.03.005
   PubMed Web of Science ®Google Scholar
• Huang L, Zhang YY, Sun LY. Time to positivity of blood culture can predict different Candida species instead of pathogen concentration in candidemia. Eur J Clin Microbiol Infect Dis. 2013;32(7):917–922. doi:10.1007/s10096-013-1826-8
   PubMed Web of Science ®Google Scholar
• Cobos-Trigueros N, Kaasch AJ, Soriano A, et al. Time to positivity and detection of growth in anaerobic blood culture vials predict the presence of Candida glabrata in candidemia: a two-center European cohort study. J Clin Microbiol. 2014;52(8):3082–3084. doi:10.1128/JCM.01198-14
   Web of Science ®Google Scholar
• Paquette K, Sweet D, Stenstrom R, et al. Neither blood culture positivity nor time to positivity is associated with mortality among patients presenting with severe manifestations of sepsis: the FABLED cohort study. Open Forum Infect Dis. 2021;8(7):ofab321. doi:10.1093/ofid/ofab321
   Web of Science ®Google Scholar
• Hsieh YC, Chen HL, Lin SY, Chen TC, Lu PL. Short time to positivity of blood culture predicts mortality and septic shock in bacteremic patients: a systematic review and meta-analysis. BMC Infect Dis. 2022;22(1):142. doi:10.1186/s12879-022-07098-8
   Web of Science ®Google Scholar
• Schroeder M, Weber T, Denker T, et al. Epidemiology, clinical characteristics, and outcome of candidemia in critically ill patients in Germany: a single-center retrospective 10-year analysis. Ann Intensive Care. 2020;10(1):142. doi:10.1186/s13613-020-00755-8
   PubMed Web of Science ®Google Scholar